Scientists have made a groundbreaking discovery that could revolutionize IVF success rates for older women by "rejuvenating" human eggs. Researchers at Ovo Labs claim to have found a way to reverse an age-related defect in embryos that causes genetic errors, potentially leading to improved egg quality and increased chances of successful pregnancies.
The breakthrough involves supplementing eggs with a crucial protein called Shugoshin 1, which declines with age and leads to premature chromosome separation. By injecting this protein into eggs donated by fertility patients, the researchers were able to reduce the number of defective eggs from 53% to 29%. In eggs from women over 35, the defect rate decreased from 65% to 44%, although the results were not statistically significant.
The approach has the potential to nearly halve the number of eggs with chromosomal abnormalities, which is a major cause of IVF failure and miscarriage in older women. According to the latest UK figures, the average birthrate for each embryo transferred in IVF treatment drops sharply after age 35, from 35% for women under 35 to just 5% for those aged 43-44.
While the technique is not expected to extend fertility beyond menopause and has yet to be tested in extensive clinical trials, the results are "really promising" according to Dr. GΓΌneΕ Taylor of the University of Edinburgh. The researchers believe that this approach could provide a game-changer for women struggling with infertility, offering a single injection that substantially increases the number of eggs with properly organized chromosomes.
The discovery is the culmination of years of research into egg biology and brings Ovo Labs one step closer to commercializing their technique. If confirmed, it could lead to improved IVF success rates and new hope for older women struggling with infertility.
The breakthrough involves supplementing eggs with a crucial protein called Shugoshin 1, which declines with age and leads to premature chromosome separation. By injecting this protein into eggs donated by fertility patients, the researchers were able to reduce the number of defective eggs from 53% to 29%. In eggs from women over 35, the defect rate decreased from 65% to 44%, although the results were not statistically significant.
The approach has the potential to nearly halve the number of eggs with chromosomal abnormalities, which is a major cause of IVF failure and miscarriage in older women. According to the latest UK figures, the average birthrate for each embryo transferred in IVF treatment drops sharply after age 35, from 35% for women under 35 to just 5% for those aged 43-44.
While the technique is not expected to extend fertility beyond menopause and has yet to be tested in extensive clinical trials, the results are "really promising" according to Dr. GΓΌneΕ Taylor of the University of Edinburgh. The researchers believe that this approach could provide a game-changer for women struggling with infertility, offering a single injection that substantially increases the number of eggs with properly organized chromosomes.
The discovery is the culmination of years of research into egg biology and brings Ovo Labs one step closer to commercializing their technique. If confirmed, it could lead to improved IVF success rates and new hope for older women struggling with infertility.